
# INTERNATIONAL VI HCM SUMMIT

# HYPERTROPHIC CARDIOMYOPATHY

Now a Global Contemporary and Treatable Disease: A Half Century of Progress

# October 15–17, 2021 A Virtual Event



**Course Directors:** Barry J. Maron, MD & Martin S. Maron, MD Jointly Provided By: Tufts Medical Center's Hypertrophic Cardiomyopathy Center & Ciné-Med In Conjunction With: Morristown Medical Center's Chanin T. Mast HCM Center & The HCMA

# DESCRIPTION

HCM Summit VII offers attendees an opportunity to learn the clinical, morphologic, and genetic spectrum of hypertrophic cardiomyopathy (HCM) from a renowned international faculty. We will explore a detailed, contemporary view of HCM in which improved diagnostic techniques and management strategies have reduced disease mortality and vastly improved thousands of patients' lives.

### TARGET GLOBAL AUDIENCE

- » Practicing cardiologists, internists, pediatricians, nurses, and other healthcare professionals with an interest in HCM throughout the world.
- » Residents, fellows, and medical students.
- » Clinicians and basic researchers directly involved with HCM.

# LEARNER OBJECTIVES/OUTCOMES

### At the completion of this activity, participants should be able to:

- » Understand the progress in contemporary management strategies for high-risk and other patient subgroups, including surgical septal myectomy, alcohol septal ablation, and prevention of sudden death with implantable defibrillators.
- » Outline the causes of sudden death in competitive athletes and the profile of HCM in athlete populations.
- » Understand differences in HCM practices and management strategies within various cultures and countries.
- » Interpret new advances in drug treatment, LV outflow obstruction relief with novel operative or percutaneous techniques, and the potential application of personalized medicine to HCM.

# ACTIVITY GOAL

This activity is designed to address the following core and team competencies:

- » Patient care
- » Medical knowledge
- » Practice-based learning
- » System-based practice
- » Evidence-based practice
- » Quality improvement

### PLANNING COMMITTEE

Martin S. Maron, MD, Director Hypertrophic Cardiomyopathy Center, Tufts Medical Center

Barry J. Maron, MD, Research Director Hypertrophic Cardiomyopathy Center, Tufts Medical Center

### FACULTY DISCLOSURE SUMMARY

Disclosure information from faculty and all others in control of content will be provided to participants prior to the beginning of the educational activity.

#### COMMERCIAL SUPPORT AND EXHIBITORS

A complete list of commercial supporters and exhibitors will be provided to participants in activity materials.

### DISCLOSURE

Ciné-Med adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee's and faculty's commercial relationships will be made known during the activity. Speakers are required to openly disclose any limitations of data and/ or discussion of off-label, experimental, or investigational uses of drugs or devices in their presentations.

#### NON-ENDORSEMENT STATEMENT

Ciné-Med verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. Ciné-Med does not endorse or support the actual opinions or material content as presented by the speakers or sponsoring organization.

### ACCREDITATION STATEMENTS



In support of improving patient care, this activity has been planned and

JOINTLY ACCREDITED PROVIDER

implemented by Ciné-Med and Tufts Medical Center. Ciné-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

### PHYSICIANS

Ciné-Med designates this live activity for a maximum of **20.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### NURSES

This activity provides **20.0 Contact** *Hours for nurses*.

### HEALTHCARE PROFESSIONALS

All other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for activities designated for *AMA PRA Category 1 Credits*™, consult your professional licensing board.

# FACULTY

Barry J. Maron, MD Tufts Medical Center Boston, MA

#### Martin S. Maron, MD Tufts Medical Center Boston, MA

Eric D. Adler, MD UC San Diego San Diego, CA

Hisham Ahamed, MD Amrita Institute of Medical Sciences Kochi, Kerala, India

Aaron L. Baggish, MD Mass General Hospital Boston, MA

**Eugene Braunwald, MD** Brigham and Women's Hospital *Boston, MA* 

Franco Cecchi, MD University of Florence Florence, Italy

Sharlene M. Day, MD University of Pennsylvania *Philadelphia, PA* 

Joseph A. Dearani, MD Mayo Clinic Rochester, MN

Milind Desai, MD Cleveland Clinic Cleveland, OH

Philip R. Fox, DVM The Animal Medical Center New York, NY

Michael Frenneaux, MD Hamad Medical Corporation Doha, Qatar

#### John L. Jefferies, MD The University of Tennessee Health Science Center Memphis. TN

Carey D. Kimmelstiel, MD Tufts Medical Center Boston, MA

Christopher M. Kramer, MD UVA Health System Charlottesville, VA

Benjamin D. Levine, MD UT Southwestern Medical Center Dallas, TX

Mark S. Link, MD UT Southwestern Medical Center Dallas, TX

Bradley A. Maron, MD Brigham and Women's Hospital Boston, MA

Matthew W. Martinez, MD Atlantic Health System Morristown, NJ

Elizabeth McNally, MD, PhD Northwestern University Evanston, IL

Michelle Michels, MD Thoraxcenter, Erasmus Medical Center Rotterdam, The Netherlands

Seema Mital, MD The Hospital for Sick Children Toronto, ON, Canada

Rick A. Nishimura, MD Mayo Clinic Rochester, MN

lacopo Olivotto, MD Careggi University Hospital Florence, Italy Steve R. Ommen MD Mayo Clinic Rochester, MN

Harry Rakowski, MD Toronto General Hospital Toronto, ON, Canada

Hassan Rastegar, MD Tufts Medical Center Boston, MA

Ethan J. Rowin, MD Tufts Medical Center Boston, MA

Frederick L. Ruberg, MD Boston Medical Center Boston, MA

Ms. Lisa Salberg Founder, HCMA Denville, NJ

Christopher Semsarian, MD The University of Sydney Sydney, NSW, Australia

Mark V. Sherrid, MD NYU Langone Health New York, NY

Paolo Spirito, MD Policlinico di Monza *Milan, Italy* 

Paul D. Thompson, MD Hartford Hospital Hartford, CT

Shuiyun Wang, MD Fuwai Hospital Beijing, China

Hugh C. Watkins, MD University of Oxford Oxford, UK

Mr. Jeff Zucker President, CNN Worldwide New York, NY

# **SPONSORS**

Sanofi Genzyme Cytokinetics, Inc. Bristol Myers Squibb

Celltrion Inc. Philips Healthcare North America

iRhythm Technologies Pfizer Inc. The Boston Scientific Corporation

> Amicus Therapeutics, Inc. Atlantic Health System Invitae Corporation John Taylor Babbitt Foundation Medtronic Rocket Pharmaceuticals, USA Zoll Medical Corporation

BioTel Heart (CardioNet) In A Heartbeat Foundation Janssen Pharmaceutica PerkinElmer Genomics Inc. Takeda Pharmaceuticals International Co.

Additional sponsors may be confirmed prior to the event. A full/final list will be provided in the day-of course syllabus.



# FRIDAY, OCTOBER 15, 2021

All Times Eastern Standard Time (U.S.)

7:30 am	EXHIBITS
8:30 am	WELCOME Martin S. Maron, MD Barry J. Maron, MD
INTRODUCTIO	N AND GENETICS
8:35–8:55 am	LECTURE. HCM: A Contemporary Treatable Disease with Low Mortality and Normal Longevity Q&A: 5 Min Barry J. Maron, MD
9:00–9:25 am	HCM and Genetic Testing Reports: Finally, Some Clarity. How Common Is Reclassification? Q&A: 10 Min Christopher Semsarian, MD
9:35–9:55 am	<b>Gene Positive–Phenotype Negative: Is It Really a Disease?</b> Q&A: 5 Min <i>Iacopo Olivotto, MD</i>
10:00–10:30 am	How Early to Screen Family Members for HCM:Pro—Very EarlySeema Mital, MDCon—Not So EarlySteven R. Ommen, MDModerator:Martin S. Maron, MDQ&A: 10 Min
10:40-11:00 am	BREAK
IMAGING	
11:00–11:25 am	<b>Echocardiography for HCMIs Strain Going to Help?</b> Q&A: 10 Min <i>Harry Rakowski, MD</i>
11:35–12:00 pm	The Doug Wigle Lecture Cardiac Magnetic Resonance in HCM: A Decade of Evidence Q&A: 10 Min Martin S. Maron, MD
12:10-12:30 pm 6	<b>Emerging Imaging Markers in HCM</b> Q&A: 5 Min <i>Christopher M. Kramer, MD</i>

## PREVENTION OF SUDDEN DEATH

12:35-1:00 pm	<b>The Paradigm of Sudden Death Prevention</b> Q&A: 10 Min <i>Martin S. Maron, MD</i>		
1:10–1:25 pm	The Maxwell Saines Lecture HCM: A Patient's Perspective Mr. Jeff Zucker—President, CNN		
1:25–2:15 pm	BREAK		
2:15–2:35 pm	Controversies in Device Therapy to Prevent Sudden Death: Single vs. Dual Chamber? Transvenous vs. Sub-Q? Q&A: 10 Min Mark S. Link, MD		
2:45–3:05 pm	<b>Challenges in Management of Syncope in HCM</b> Q&A: 5 Min <i>Michael Frenneaux, MD</i>		
3:10–3:35 pm	HCM for Pediatric Cardiologists: Nomenclature, Syndromes, Managementand Sudden Death Prevention. Is It a Different Disease in Children? Q&A: 10 Min John L. Jefferies, MD		
3:45–4:25 pm	Differential Diagnosis: D Danon (LAMP 2) Disease Cardiac Amyloidosis Fabry Disease Athlete's Heart Q&A: 10 Min	<b>Diseases That Look Like HCM</b> Eric D. Adler, MD Frederick L. Ruberg, MD Franco Cecchi, MD Aaron L. Baggish, MD	
4:35–5:00 pm	<b>Reflections on the History of HCMfrom the Father of HCM</b> Q&A: 10 Min <i>Eugene Braunwald, MD</i>		
5:10 pm	ADJOURN		



7:30 am EXHIBITS

### **REVERSIBILITY OF HEART FAILURE**

8:30–8:55 am	Importance of Outflow Obstruction: Reversibility of Heart Failure Q&A: 10 Min Barry J. Maron, MD
9:05–9:25 am	Anatomic Complexity of Obstruction: Contribution of Mitral Valve and Submitral Structures Q&A: 5 Min Milind Desai, MD
9:30–9:55 am	Surgical Septal Myectomy: The Low Risk, High Benefit Gold Standard Treatment for Obstructive HCM Q&A: 10 Min Joseph A. Dearani, MD
10:05–10:25 am	BREAK
10:25-10:45 am	Why Are We Not Operating Earlier for Obstructive HCM? Q&A: 10 Min Paolo Spirito, MD
10:55–11:15 am	Alcohol Septal Ablation: Who, When, and Why? Q&A: 10 Min Carey D. Kimmelstiel, MD
11:25–11:50 am	<b>Myectomy and Ablation: Putting it All Together:</b> <b>From a Master</b> Q&A: 10 Min <i>Rick A. Nishimura, MD</i>

12:00-12:50 pm BREAK

### MEDICAL TREATMENT FOR OBSTRUCTION

12:50–1:15 pm The Resurrection of Disopyramide Q&A: 5 Min Mark V. Sherrid, MD

1:20–1:45 pm	Myosin Inhibitors: What Will Change? Iacopo Olivotto, MD
1:45-2:10 pm	Myosin Inhibitors:In Need of Perspective Q&A: 15 Min (Combined for Myosin Inhibitors) Martin S. Maron, MD
2:25-2:35 pm	BREAK
ATRIAL FIBRIL	LATION, PULMONARY HYPERTENSION AND TIVE HCM
2:35–3:00 pm	Atrial Fibrillation: New Perspectives on Natural History/ Management Q&A: 10 Min Ethan J. Rowin, MD
3:10–3:20 pm	Surgical Treatment for Atrial Fibrillation: Cox-Maze IV Combined with Myectomy Q&A: 5 Min Hassan Rastegar, MD
3:25–3:50 pm	Pulmonary Hypertension in HCM: Overlooked, But Not Forgotten Q&A: 10 Min Bradley A. Maron, MD
4:00–4:25 pm	Nonobstructive HCM: Benign? End-Stage Heart Failure/ Transplant and Progress Q&A: 10 Min Ethan J. Rowin, MD
4:35–4:55 pm	HCM and Takotsubo: Strange Bedfellows Q&A: 5 Min Mark V. Sherrid, MD
5:00- 8:00 pm	HCMA: Patient Perspectives and Voices Ms. Lisa Salberg—Founder, HCMA



8:00 am	EXHIBITS		
OTHER IMPOR	RTANT ISSUES		
9:00-9:25 am	Impact of Gender and Race in HCM Q&A: 5 Min Michelle Michels, MD, PhD		
9:30–9:55 am	Gray Areas in HCM: Ask the Master Q&A: 10 Min Steven R. Ommen, MD Moderator: Barry J. Maron, MD		
10:05–10:30 am	Exercise in HCM: How Much is OK—or Enough—and What Kind Q&A: 10 Min, Benjamin D. Levine, MD		
10:40–11:10 am	Athletes with HCM: Should They Play?Q&A: 15 MinProSharlene M. Day, MDConPaul D. Thompson, MDModerator: Martin S. Maron, MD		
11:25-11:40 am	Athletes with COVID-19: Should They Play? Q&A: 5 Min Matthew Martinez, MD		
11:45–12:05 pm	BREAK		
12:05–12:55 pm	What Causes HCM? Q&A: 10 Min Single Sarcomere Mutations Are Responsible for HCM Elizabeth McNally, MD		
	Wait a MinuteAre We Really Sure Sarcomere Mutations Are the Cause?, Bradley A. Maron, MD		
	Moderator: Martin S. Maron, MD		
12:55-1:30 pm	<b>Did You Know HCM is Also a Very Important Disease in Cats?</b> Q&A: 5 Min, <i>Phil R. Fox, DVM</i>		
1:30-2:00 pm	<b>Establishing a Large HCM Center in the Developing World</b> Q&A: 5 Min, <i>Hisham Ahamed, MD</i>		
2:00-2:30 pm	<b>Global Expanse of Surgical Myectomy to China</b> Q&A: 5 Min, <i>Shuiyun Wang, MD</i>		
2:30–3:10 pm	DEBATE: Curing HCMQ&A: 10 MinIs a Cure Coming?Hugh C. Watkins, MDOr Is It Already Here?Barry J. Maron, MDModerator: Martin S. Maron, MD		
3:10-3:20 pm	EPILOGUE: The Future Burns Bright Around the World, Martin S. Maron, MD		
3:20 pm	ADJOURN		
10			

# TUITION AND REGISTRATION

Registration confirmation, conference details, and post-event survey will be sent via email. Approximately one week prior to Summit VII you will receive a reminder email including instructions on how to login virtually. If you do not receive these communications, please contact us to verify your registration.

### TUITION

- \$350 physicians (with CME credit)
- **\$150** physicians (*without* CME credit)
- \$100 health professionals and patients

Tuition includes Summit VII materials. Advanced registration is required and will be accepted until **Thursday**, October 7, 2021.

# PAYMENT

**Register and pay online at hcmsummit.org.** Visa, MasterCard, American Express, or Discover accepted. You may also register and pay via check by mailing this completed form to: ATTN: Emily Lalone, Lalone Marketing, 84 Cedar Street, Amesbury, MA 01913, USA. Make checks payable to: **Tufts Medical Center, Inc.** 

### PLEASE PRINT

irst and Last Name
mail
hone (Daytime)
redentials/Job Title
mployer
ddress
ddress
ity/State/Zip

# CANCELLATION AND REFUND POLICY

**Prior to October 1, 2021**, cancellation will result in refunded tuition minus a \$50 processing fee per registrant. Cancellation requests after this date will not receive refunds. Substitutions are accepted at any time. To complete your cancellation or substitution email team@lalonemarketing.com.

In the unlikely event of the Summit VII's cancellation, Ciné-Med, the Hypertrophic Cardiomyopathy Center at Tufts Medical Center, and the event organizers are not responsible for costs incurred by participants. We reserve the right to cancel a session or substitute a qualified speaker if an emergency arises.

# QUESTIONS

For questions about Summit VII, please email team@lalonemarketing.com.

800 Washington Street, #70 Boston, Massachusetts 02111



NonProfit Org. U.S. Postage **PAID** Brockton, MA Permit No. 402